人膀胱癌原代培养体外药敏试验的研究

目的:探讨用ATP生物荧光肿瘤体外药敏检测技术(ATP-TCA)研究膀胱癌药敏的异质性和个体化疗的可行性。方法:用ATP-TCA检测来自45例初发和6例复发膀胱癌患者的手术标本对4种化疗药物的敏感程度。结果:51例标本中有49例获得药敏结果,可评价率为96·0%。最有活性的药物是吡柔比星,有43·8%(21/48)的标本对它表现强敏感;28·6%(14/49)的标本无强敏感药物;69·4%(34/49)的标本无耐药药物。结论:膀胱癌对抗癌药物的敏感程度存在着异质性。ATP生物荧光肿瘤药敏检测技术可用于为膀胱癌选择合适的化疗药物。

Evaluation of chemosensitivity of human bladder cancer determined by primary culture assay in vitro

Objective:To investigate the heterogeneity of chemosensitivity in bladder cancer using an ATP-tumor chemosensitivity assay (ATP-TCA) and the feasibility of individual chemotherapy. Methods:An ATP-tumor chemosensitivity assay (ATP-TCA) were used to determine the effect of 4 cytotoxic drugs in surgical specimens from 51 patients with primary (n=45) or recurrent (n=6) bladder cancer. Results:Evaluable test results were achieved in 49 of 51 patients. The evaluability rate was 96%. The most active drug in the assay was identified as pirarubicin, for 43.8% (21/48) specimens were super-sensitivity to it. 28.6% specimens were not be super-sensitivity to any drugs tested, whereas 69.4% specimens were not to be resistant to any drugs tested. Conclusion: There is the heterogeneity of the chemosensitivity in bladder cancer in vitro. The use of the ATP-TCA provides a method of selecting appropriate anti-cancer drugs in bladder cancer.